Mackay Shields LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mackay Shields LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,897	Closed	-$234K	–	1431
2020 Q2	$234K	Sell	1,897 -500	-21%	-$49.7K	﹤0.01%	1351
2020 Q1	$203K	Sell	2,397 -1,000	-29%	-$86.2K	﹤0.01%	1292
2019 Q4	$288K	Sell	3,397 -900	-21%	-$68K	﹤0.01%	1234
2019 Q3	$290K	Buy	4,297 +1,000	+30%	+$77K	﹤0.01%	1335
2019 Q2	$283K	Sell	3,297 -29,825	-90%	-$2.55M	﹤0.01%	1347
2019 Q1	$2.94M	Sell	33,122 -7,901	-19%	-$732K	0.02%	607
2018 Q4	$3.49M	Buy	+41,023	New	+$3.9M	0.03%	554

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackay Shields LLC's BMRN Position: Q3 2020 in Review

Mackay Shields LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 1,897 shares — an estimated $234K sold.

Mackay Shields LLC first reported a position in BMRN in Q4 2018 and held it in 7 quarters. The position peaked at $3.49M in Q4 2018. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Mackay Shields LLC reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Mackay Shields LLC sold 1,897 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $234K.
Mackay Shields LLC first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 7 quarters.
Mackay Shields LLC's BioMarin Pharmaceuticals position peaked at $3.49M in Q4 2018.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.